Menu
Login

Report Library

All Reports

2019 Biomedtracker / Datamonitor Healthcare Pre-ASCO Podcast

May 24, 2019

Abstracts from the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) were released May 15th at 5pm EDT. The 2019 ASCO meeting will be held in Chicago, Illinois, from May 31 - June 4, 2019. This audio-only podcast features Informa Pharma Intelligence analysts who preview notable presentations related to the upcoming 2019 American Society for Clinical Oncology Annual Meeting. Join them as they discuss interesting topics and abstracts from this year's meeting.

Topics include:
  • AstraZeneca’s late breaking abstract will present the first numerical results for POLO, a Phase III trial evaluating Lynparza as single-agent maintenance therapy for frontline, BRCA mutant pancreatic cancer after platinum chemotherapy. In February 2019 AstraZeneca announced that POLO met its primary endpoint of improvement in progression-free survival. Here, we discuss the landscape for PARP inhibitors for pancreatic cancer and what’s next for Lynparza. (1:26)
  • Forty Seven will present early data from a Phase Ib trial in AML and MDS of 5F9, a macrophage checkpoint inhibitor. Updates for 5F9 in DLBCL and follicular lymphoma are expected at EHA. Here, we compare 5F9’s activity in DLBCL with Roche’s polatuzumab vedotin and MorphoSys’ MOR208. (6:01)
  • Data from the Phase III ANNOUNCE trial will provide color on the surprise failure of Lartruvo in sarcoma. (11:53)
  • Positive OS results for Kisqali in the MONALEESA-7 trial could help boost uptake in HR+/HER2- breast cancer. (16:28)
  • Strong OS data for Xtandi in the ENZAMET trial will help it keep pace with current and future next-generation hormone therapies in prostate cancer. (21:34)
  • Context for the late-breaking presentation that will show more details on the EV-201 trial, testing enfortumab vedotin in bladder cancer. (27:03)
  • Discussion on the late breaking presentation for KEYNOTE-062, and competitive landscape in first-line gastric cancer (33:13)
  • Thoughts around initial Phase I data for AMG 510, a small molecule KRAS inhibitor, in NSCLC and colorectal cancer. (38:15)



As a reminder, our ASCO coverage will continue throughout the conference and beyond. Our coverage will include:
  • June 3 - ASCO Weekend Update
  • Shortly following the conference - Post-ASCO Report
For our disclosures, please read the Biomedtracker Research Standards.
Disease Group Covered: Oncology

 Additional Resources: